Inventor · disambiguated record
Maria Di Fluri
Also filed as: DI FLURI MARIA R · DI FLURI MARIA ROSARIA
9 granted patents·4 pending applications·124 citations·filing 2002–2022
88Inventor score
Top patents by PatentIndex Score
13 records- 0194US7354934B2Chemokine receptor binding heterocyclic compounds with enhanced efficacyANORMED INC·Filed 2005·Granted Apr 8, 2008·34 cites·10 claims
- 0293US7091217B2Chemokine receptor binding heterocyclic compoundsANORMED INC·Filed 2004·Granted Aug 15, 2006·31 cites·12 claims
- 0390US7354932B2Chemokine receptor binding heterocyclic compounds with enhanced efficacyANORMED INC·Filed 2003·Granted Apr 8, 2008·27 cites·21 claims
- 0489US8778967B2Chemokine receptor binding heterocyclic compounds with enhanced efficacyBRIDGER GARY·Filed 2012·Granted Jul 15, 2014·18 cites·20 claims
- 0576US7396840B2Chemokine receptor binding heterocyclic compoundsGENZYME CORP·Filed 2006·Granted Jul 8, 2008·1 cites·9 claims
- 0675US7312234B2Chemokine receptor binding heterocyclic compoundsANORMED·Filed 2004·Granted Dec 25, 2007·7 cites·6 claims
- 0769US7084155B2Chemokine receptor binding heterocyclic compoundsANORMED·Filed 2004·Granted Aug 1, 2006·3 cites·15 claims
- 0867US2020000774A1Chemokine receptor binding heterocyclic compounds with enhanced efficacyGENZYME CORP·Filed 2019·Application pending·0 cites
- 0966US7491735B2Chemokine receptor binding compoundsGENZYME CORP·Filed 2004·Granted Feb 17, 2009·3 cites·6 claims
- 1062US7807694B2Chemokine receptor binding heterocyclic compoundsGENZYME CORP·Filed 2006·Granted Oct 5, 2010·0 cites·4 claims
- 1162US2008167341A1Chemokine receptor binding heterocyclic compounds with enhanced efficacyBRIDGER GARY·Filed 2008·Application pending·0 cites
- 1259US2022409589A1Chemokine receptor binding heterocyclic compounds with enhanced efficacyGENZYME CORP·Filed 2022·Application pending·0 cites
- 1349US2003220341A1Chemokine receptor binding heterocyclic compounds with enhanced efficacyFiled 2002·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →